TWI860281B - 廣效型抗病毒治療的組合物及方法 - Google Patents

廣效型抗病毒治療的組合物及方法 Download PDF

Info

Publication number
TWI860281B
TWI860281B TW107136527A TW107136527A TWI860281B TW I860281 B TWI860281 B TW I860281B TW 107136527 A TW107136527 A TW 107136527A TW 107136527 A TW107136527 A TW 107136527A TW I860281 B TWI860281 B TW I860281B
Authority
TW
Taiwan
Prior art keywords
virus
mers
cov
cells
viral
Prior art date
Application number
TW107136527A
Other languages
English (en)
Chinese (zh)
Other versions
TW201927293A (zh
Inventor
碩峰 袁
福和 陳
軒 朱
耀南 劉
國勇 袁
Original Assignee
香港商港大科橋有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 香港商港大科橋有限公司 filed Critical 香港商港大科橋有限公司
Publication of TW201927293A publication Critical patent/TW201927293A/zh
Application granted granted Critical
Publication of TWI860281B publication Critical patent/TWI860281B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW107136527A 2017-10-18 2018-10-17 廣效型抗病毒治療的組合物及方法 TWI860281B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762573933P 2017-10-18 2017-10-18
US62/573,933 2017-10-18

Publications (2)

Publication Number Publication Date
TW201927293A TW201927293A (zh) 2019-07-16
TWI860281B true TWI860281B (zh) 2024-11-01

Family

ID=66173467

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107136527A TWI860281B (zh) 2017-10-18 2018-10-17 廣效型抗病毒治療的組合物及方法

Country Status (6)

Country Link
US (1) US12213955B2 (https=)
EP (1) EP3697404B1 (https=)
JP (1) JP7466907B2 (https=)
CN (1) CN111886008B (https=)
TW (1) TWI860281B (https=)
WO (1) WO2019079339A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089306A1 (en) 2016-11-10 2018-05-17 Oyagen, Inc. Methods of treating and inhibiting ebola virus infection
CN112789925B (zh) * 2019-06-27 2023-06-02 Oppo广东移动通信有限公司 用于指示空间关系信息的方法和设备
US11738025B2 (en) 2020-02-04 2023-08-29 Oyagen, Inc. Method for treating coronavirus infections
AU2021235899A1 (en) * 2020-03-08 2022-10-13 Humanigen, Inc. Methods for treating coronavirus infection and resulting inflammation-induced lung injury
US11628165B1 (en) * 2020-03-25 2023-04-18 Helen Feng Method of boosting immune system against viral infection
ES2862462B2 (es) * 2020-04-06 2023-04-27 Servicio Andaluz De Salud Compuestos para la profilaxis y/o el tratamiento del sindrome de dificultad respiratoria aguda
WO2021211738A1 (en) * 2020-04-15 2021-10-21 Sanford Burnham Prebys Medical Discovery Institute Methods and compositions for antiviral treatment
WO2021226479A1 (en) * 2020-05-07 2021-11-11 The Regents Of The University Of California Inhaled statins for treatment of viral respiratory diseases
BR112022023746A2 (pt) * 2020-05-22 2023-02-07 Alberto Riveros Carlos Sistema, método e uso de um determinado medicamento para reduzir a replicação viral na mucosa das vias aéreas
WO2021249240A1 (zh) * 2020-06-11 2021-12-16 养生堂有限公司 Palovarotene在抗hbv病毒治疗中的用途
US20240131036A1 (en) * 2020-07-02 2024-04-25 The Uab Research Foundation Compositions and methods of treating conditions
CN112390731B (zh) * 2020-11-16 2022-11-25 成都大学 一种具有多靶点的维甲酸类衍生物及其制备方法与应用
US11998562B2 (en) 2021-01-25 2024-06-04 University Of South Florida Ophthalmological formulations for the prevention of a coronavirus infection
CN117062611A (zh) 2021-01-26 2023-11-14 惠和生物技术(上海)有限公司 嵌合抗原受体（car）构建体和表达car构建体的nk细胞
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery
CN116891497B (zh) * 2022-04-02 2025-12-16 上海旭成医药科技有限公司 视黄酸受体激动剂、其制备方法、中间体、药物组合物和应用
WO2023210634A1 (ja) * 2022-04-28 2023-11-02 国立大学法人東海国立大学機構 拡張障害を伴う心不全の治療用医薬組成物
CN119454680B (zh) * 2024-12-06 2025-06-17 华南农业大学 贝沙罗汀在制备抗prrsv或治疗猪蓝耳病的药物中的应用
CN121177272A (zh) * 2025-11-10 2025-12-23 北京市农林科学院 化合物am580在预防或治疗塞内卡病毒病中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120479A1 (en) * 2004-06-09 2005-12-22 Gpc Biotech Ag Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
WO2014079709A1 (en) * 2012-11-23 2014-05-30 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
CN106572663A (zh) * 2014-03-10 2017-04-19 康奈尔大学 用于头颈癌的联合疗法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7341717B2 (en) 2001-04-13 2008-03-11 Gpc Biotech Ag Therapeutic targets for treatment of HCV infections, methods of treating HCV infections and compounds useful therefor
US20060151574A1 (en) * 2002-11-29 2006-07-13 Gpc Biotech Ag Formulations useful against hepatitis C virus infections
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
ES2609825T3 (es) * 2007-01-18 2017-04-24 Evolva Sa 1,3-Dioxanos sustituidos útiles como moduladores de PPAR
CN104662036B (zh) * 2012-04-25 2018-11-09 华辉安健（北京）生物科技有限公司 乙肝肝炎病毒功能性受体的组成以及相关应用
KR20160113302A (ko) 2014-02-18 2016-09-28 칠드런＇스 하스피틀 로스 앤젤레스 호중구감소증을 치료하기 위한 조성물 및 방법
WO2018054891A1 (en) 2016-09-20 2018-03-29 Ruprecht-Karls-Universität Compounds and combinations thereof for preventing and/or treating hbv and/or hdv infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120479A1 (en) * 2004-06-09 2005-12-22 Gpc Biotech Ag Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
WO2014079709A1 (en) * 2012-11-23 2014-05-30 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
CN106572663A (zh) * 2014-03-10 2017-04-19 康奈尔大学 用于头颈癌的联合疗法

Also Published As

Publication number Publication date
US20200338032A1 (en) 2020-10-29
EP3697404B1 (en) 2025-03-26
JP7466907B2 (ja) 2024-04-15
CN111886008A (zh) 2020-11-03
EP3697404A1 (en) 2020-08-26
JP2021500400A (ja) 2021-01-07
TW201927293A (zh) 2019-07-16
WO2019079339A1 (en) 2019-04-25
US12213955B2 (en) 2025-02-04
CN111886008B (zh) 2024-05-31
EP3697404A4 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
TWI860281B (zh) 廣效型抗病毒治療的組合物及方法
Pizzato et al. SARS-CoV-2 and the host cell: a tale of interactions
Yuan et al. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target
Prajapat et al. Drug targets for corona virus: A systematic review
Wang et al. Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2
Boriskin et al. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion
Pan et al. Nonsteroidal anti-inflammatory drugs potently inhibit the replication of Zika viruses by inducing the degradation of AXL
Li et al. NPC1-regulated dynamic of clathrin-coated pits is essential for viral entry
US20140121237A1 (en) Methods for Inhibiting Virus Replication
Raj et al. COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics—a review
US20210145795A1 (en) Soce facilitators for use in treating or preventing viral infections
Siwak et al. Cellular sialoglycans are differentially required for endosomal and cell-surface entry of SARS-CoV-2 in lung cell lines
Tang et al. Peptide-based inhibitors hold great promise as the broad-spectrum agents against coronavirus
Steele et al. The role of sialylation in respiratory viral infection and treatment
Raj et al. Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19
Hayn et al. Imperfect innate immune antagonism renders SARS-CoV-2 vulnerable towards IFN-γ and-λ
Li et al. Differential Bioactivation Profiles of Different GS-441524 Prodrugs in Cell and Mouse Models: ProTide Prodrugs with High Cell Permeability and Susceptibility to Cathepsin A Are More Efficient in Delivering Antiviral Active Metabolites to the Lung
HK40038027B (zh) 用於抗mers-冠状病毒治疗的组合物和方法
HK40038027A (en) Compositions and methods for anti-mers-coronavirus therapy
WO2022072745A1 (en) Methods and compositions to treat and prevent viral infections and acute respiratory distress syndrome
US20230002774A1 (en) Methods and compostions for inhibiting coronaviral replication
WO2021228037A1 (en) Compositions and methods for broad spectrum anti-viral therapy
Sopetto SARS-CoV-2 and the Host Cell: A Tale of Interactions
US10883980B2 (en) Methods and compositions for inhibiting hepatitis E virus
Mekhail Investigating the Role of Fatty-Acid Synthesis and S-Palmitoylation on Coronavirus Infection